BR112019006113A2 - métodos de tratamento de distúrbios mitocondriais e metabólicos - Google Patents
métodos de tratamento de distúrbios mitocondriais e metabólicosInfo
- Publication number
- BR112019006113A2 BR112019006113A2 BR112019006113A BR112019006113A BR112019006113A2 BR 112019006113 A2 BR112019006113 A2 BR 112019006113A2 BR 112019006113 A BR112019006113 A BR 112019006113A BR 112019006113 A BR112019006113 A BR 112019006113A BR 112019006113 A2 BR112019006113 A2 BR 112019006113A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- metabolic disorders
- treating mitochondrial
- mitochondrial
- allosteric inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nanotechnology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
a presente invenção refere-se a métodos e composições para o tratamento de doenças, tais como distúrbios associados às mitocôndrias, por exemplo, síndrome de leigh, de melas, e de narp, e distúrbios metabólicos, compreendendo administrar um inibidor de mtor alostérico, tal como uma composição compreendendo nanopartículas compreendendo um inibidor de mtor alostérico e uma albumina. são também fornecidos medicamentos e kits úteis para os métodos descritos aqui.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662401092P | 2016-09-28 | 2016-09-28 | |
PCT/US2017/054149 WO2018064405A1 (en) | 2016-09-28 | 2017-09-28 | Methods of treating mitochondrial and metabolic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019006113A2 true BR112019006113A2 (pt) | 2019-06-18 |
Family
ID=61763007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019006113A BR112019006113A2 (pt) | 2016-09-28 | 2017-09-28 | métodos de tratamento de distúrbios mitocondriais e metabólicos |
Country Status (14)
Country | Link |
---|---|
US (1) | US20190307732A1 (pt) |
EP (1) | EP3518923A4 (pt) |
JP (2) | JP2019529474A (pt) |
KR (2) | KR102475256B1 (pt) |
CN (1) | CN110022876A (pt) |
AU (1) | AU2017335902B2 (pt) |
BR (1) | BR112019006113A2 (pt) |
CA (1) | CA3038824A1 (pt) |
CL (1) | CL2019000787A1 (pt) |
EA (1) | EA201990820A1 (pt) |
IL (1) | IL265566A (pt) |
MA (1) | MA46365A (pt) |
MX (1) | MX2019003397A (pt) |
WO (1) | WO2018064405A1 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2117520T (lt) | 2006-12-14 | 2018-12-10 | Abraxis Bioscience, Llc | Krūties vėžio terapija hormonų receptoriaus statuso pagrindu su nanodalelėmis, apimančiomis taksaną |
WO2011123393A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
ES2897991T3 (es) | 2015-06-29 | 2022-03-03 | Abraxis Bioscience Llc | Nanopartículas que comprenden sirolimus y una albúmina para uso en tratamiento de tumores de células epitelioides |
EP3768268A4 (en) | 2018-03-20 | 2022-02-23 | Abraxis BioScience, LLC | METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE |
CN112423737A (zh) * | 2018-05-22 | 2021-02-26 | 阿布拉科斯生物科学有限公司 | 用于治疗肺高压的方法和组合物 |
AU2020241730A1 (en) * | 2019-03-19 | 2021-10-28 | Abraxis Bioscience, Llc | Subcutaneous administration of nanoparticles comprising an mTOR inhibitor and albumin for treatment of diseases |
JP2022553426A (ja) | 2019-10-28 | 2022-12-22 | アブラクシス バイオサイエンス, エルエルシー | アルブミンおよびラパマイシンの医薬組成物 |
CN111621556A (zh) * | 2019-12-31 | 2020-09-04 | 安徽医科大学第一附属医院 | 一种检测人线粒体atp6基因8993位点基因型的试剂盒及方法 |
CN111419876A (zh) * | 2020-04-30 | 2020-07-17 | 复旦大学附属中山医院 | 线粒体移植在治疗原发性扩心病中的应用 |
CN112972681B (zh) * | 2021-01-27 | 2022-06-07 | 西安交通大学 | Mt-nd6作为新靶点在代谢综合征诊断和治疗药物中的应用 |
CN114848795B (zh) * | 2021-02-03 | 2023-04-14 | 四川大学 | RORa蛋白及其激动剂在制备抗衰老药物中的应用 |
CN114507677B (zh) * | 2022-02-16 | 2023-09-05 | 中国人民解放军空军军医大学 | Ndufs1基因在治疗心梗后心衰中的应用和相关产品 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2005106855A (ru) * | 2002-08-12 | 2005-10-10 | Дзе Риджентс оф дзе Юниверсити оф Мичиган (US) | Диагностика и лечение заболеваний, вызываемых дефектами каскада реакций, обусловливающих туберозный склероз |
EP1853610A1 (en) | 2005-03-03 | 2007-11-14 | Sirtris Pharmaceuticals, Inc. | N-phenyl benzamide derivatives as sirtuin modulators |
US20090029904A1 (en) * | 2006-07-21 | 2009-01-29 | Sean Oldham | Compositions and methods for treatment of insulin-resistance diseases |
CN101730526A (zh) * | 2007-03-07 | 2010-06-09 | 阿布拉科斯生物科学有限公司 | 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒 |
EP3417859A1 (en) * | 2007-03-07 | 2018-12-26 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
CA2686736A1 (en) * | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension |
PT2365802T (pt) * | 2008-11-11 | 2017-11-14 | Univ Texas | Microcápsulas de rapamicina e utilização para o tratamento de cancro |
WO2011123393A1 (en) * | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
AU2012249371B2 (en) * | 2011-04-28 | 2017-06-08 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
US9180134B2 (en) * | 2011-08-18 | 2015-11-10 | Ecole Polytechnique Federale De Lausanne (Epel) | Mitochondrial ribosomal proteins as aging regulators |
WO2014151853A1 (en) * | 2013-03-14 | 2014-09-25 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
BR112016010716A8 (pt) | 2013-11-13 | 2020-04-22 | Novartis Ag | dose de reforço imunológico, baixa, de um inibidor de mtor, seu uso, e adjuvante de vacina |
WO2016134486A1 (en) * | 2015-02-27 | 2016-09-01 | Steinberg Gregory | Use of canagliflozin and derivatives thereof in the treatment of cancer |
WO2017096270A1 (en) * | 2015-12-03 | 2017-06-08 | The Regents Of The University Of California | Methods for treating mitochondrial diseases |
-
2017
- 2017-09-28 EA EA201990820A patent/EA201990820A1/ru unknown
- 2017-09-28 CN CN201780072508.4A patent/CN110022876A/zh active Pending
- 2017-09-28 EP EP17857459.6A patent/EP3518923A4/en active Pending
- 2017-09-28 KR KR1020197011866A patent/KR102475256B1/ko active IP Right Grant
- 2017-09-28 KR KR1020227042293A patent/KR20230003239A/ko not_active Application Discontinuation
- 2017-09-28 JP JP2019516447A patent/JP2019529474A/ja active Pending
- 2017-09-28 BR BR112019006113A patent/BR112019006113A2/pt active Search and Examination
- 2017-09-28 US US16/336,390 patent/US20190307732A1/en active Pending
- 2017-09-28 AU AU2017335902A patent/AU2017335902B2/en active Active
- 2017-09-28 CA CA3038824A patent/CA3038824A1/en active Pending
- 2017-09-28 WO PCT/US2017/054149 patent/WO2018064405A1/en active Application Filing
- 2017-09-28 MX MX2019003397A patent/MX2019003397A/es unknown
- 2017-09-28 MA MA046365A patent/MA46365A/fr unknown
-
2019
- 2019-03-24 IL IL265566A patent/IL265566A/en unknown
- 2019-03-26 CL CL2019000787A patent/CL2019000787A1/es unknown
-
2022
- 2022-09-16 JP JP2022148199A patent/JP2022191238A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190307732A1 (en) | 2019-10-10 |
IL265566A (en) | 2019-05-30 |
CL2019000787A1 (es) | 2019-05-31 |
KR20190060797A (ko) | 2019-06-03 |
AU2017335902B2 (en) | 2023-08-24 |
CN110022876A (zh) | 2019-07-16 |
WO2018064405A1 (en) | 2018-04-05 |
AU2017335902A1 (en) | 2019-04-18 |
JP2019529474A (ja) | 2019-10-17 |
MX2019003397A (es) | 2019-06-06 |
EP3518923A4 (en) | 2020-06-17 |
EP3518923A1 (en) | 2019-08-07 |
CA3038824A1 (en) | 2018-04-05 |
EA201990820A1 (ru) | 2019-10-31 |
KR20230003239A (ko) | 2023-01-05 |
MA46365A (fr) | 2019-08-07 |
KR102475256B1 (ko) | 2022-12-08 |
JP2022191238A (ja) | 2022-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019006113A2 (pt) | métodos de tratamento de distúrbios mitocondriais e metabólicos | |
CO2019007863A2 (es) | Derivados de benzooxazol como inmunomoduladores | |
ECSP19030002A (es) | 1,2,4-triazolonas 2,4,5-trisustituidas | |
ECSP20069418A (es) | Compuestos heterocíclicos como inmunomoduladores | |
CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
BR112017020999A2 (pt) | inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer | |
DOP2019000206A (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas | |
BR112017027954A2 (pt) | métodos de tratamento de tumores de célula epitelioide | |
CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
BR112015024530A2 (pt) | composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto | |
BR112018070123A2 (pt) | oxiesterós e métodos de uso dos mesmos | |
BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto | |
BR112018072034A2 (pt) | compostos mic-1 e usos dos mesmos | |
BR112015019412A2 (pt) | inibidores de bace1 | |
TR201900148T4 (tr) | Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin. | |
BR112015022577A2 (pt) | moduladores ship1 e métodos relacionados a esse | |
BR112017008103A2 (pt) | composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo. | |
BR112016007329A2 (pt) | composto, composição farmacêutica, e, método para tratamente de uma condição ou doença mediada por hsf1 | |
CO2019002523A2 (es) | Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica | |
BR112017010602A2 (pt) | análogos de ureia ligados em ponte substituídos como moduladores de sirtuína | |
BR112019006880A2 (pt) | compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos | |
UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
MX2022000945A (es) | Composicion para incrementar la expresion de pgc-1alfa. | |
EA201792264A1 (ru) | Способы лечения воспалительных заболеваний |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |